NSPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NSPR is not a good buy right now for a beginner investor focused on long-term investing, especially with $50,000-$100,000 to deploy. The stock is technically weak, there is no strong proprietary buy signal, the company is dealing with a recent recall and withdrawn guidance, and the current setup looks more like a speculative turnaround than a stable long-term entry. I would not buy it at this time.
The short-term trend is bearish despite the stock being oversold. MACD histogram is negative and worsening, RSI_6 is 17.589, which shows oversold conditions, but oversold alone is not a buy signal. The moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Current pre-market price of 0.7645 is just above S1 at 0.757 and below the pivot at 0.879, which means the stock is trading in a weak zone with limited evidence of reversal. The pattern-based estimate suggests some near-term bounce potential, but that is not enough to override the broader bearish trend.
["Piper Sandler still keeps an Overweight rating and described the situation as manageable.", "Lake Street keeps a Buy rating and views the recall issue as contained to the delivery system.", "Q1 sales were $3.4M, above the $2.7M estimate, showing better-than-expected quarterly performance.", "The company has positive support around its micromesh carotid stent technology.", "The stock is technically oversold, which could allow for a short-term bounce."]
["Recent voluntary recall of the CGuard Prime 135 cm delivery system disrupted the U.S. launch.", "The company withdrew its 2026 revenue guidance of $13M-$15M.", "Lake Street cut its 2026 revenue estimate from $13M to $8.8M.", "There is no news in the recent week to create a fresh positive catalyst.", "No strong AI Stock Picker or SwingMax signal is present today.", "Insiders and hedge funds show no notable positive trading trend.", "No recent congress trading data is available.", "Technical trend remains bearish and below key resistance levels."]
Latest available quarter was Q1 2026. InspireMD reported sales of $3.4M, beating the $2.7M consensus estimate. That indicates solid top-line momentum in the quarter, helped by both U.S. and international business strength. However, the later product recall and temporary discontinuation of U.S. commercial activity weaken the forward-looking growth picture, and the company withdrew full-year 2026 revenue guidance, which is a major negative for long-term visibility.
Recent analyst sentiment is still constructive but clearly less bullish on price targets. Piper Sandler lowered its target from $4 to $3 while keeping Overweight, and Lake Street cut its target from $5 to $4 while keeping Buy. The pro view is that the technology remains attractive and the recall is manageable/contained. The con view is that the U.S. launch setback and reduced revenue expectations materially hurt near-term execution. Overall, Wall Street remains positive on the story, but the target cuts show confidence has moderated.
